Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q2 2023 Laboratory & Diagnostic Services Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q2 2023 Laboratory & Diagnostic Services Update

Lab & diagnostic services experienced a rebound in transaction volume in Q2 relative to the depressed volume seen in Q1. Despite constricted lending markets, valuation multiples have remained elevated for premium assets. Large players such as Quest Diagnostics and Labcorp continue to expand their national presence and diagnostic service offerings through add-on acquisitions.

Over the past four quarters, deal flow from strategic buyers in the lab & diagnostic services sector has substantially outpaced that of financial sponsors. Synergies such as test menu expansion, payor pressure to lower costs, and customer acquisition are driving increased competition for add-ons. Innovation continues to be the main catalyst for premium valuations from strategic acquirers as consolidators look to establish a differentiated diagnostic solution.

To print and download the full Laboratory & Diagnostic Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2023/07/Q2-2023-Newsletter-Package_Lab-Dx.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]